Filament Health (NEOE:FH) FCF Margin % : -236.32% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Filament Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Filament Health's Free Cash Flow for the three months ended in Dec. 2024 was C$-0.45 Mil. Filament Health's Revenue for the three months ended in Dec. 2024 was C$0.19 Mil. Therefore, Filament Health's FCF Margin % for the quarter that ended in Dec. 2024 was -236.32%.

As of today, Filament Health's current FCF Yield % is -25.53%.

The historical rank and industry rank for Filament Health's FCF Margin % or its related term are showing as below:

NEOE:FH' s FCF Margin % Range Over the Past 10 Years
Min: -1084.38 Med: -379.09 Max: -199.25
Current: -379.09

During the past 5 years, the highest FCF Margin % of Filament Health was -199.25%. The lowest was -1084.38%. And the median was -379.09%.

NEOE:FH's FCF Margin % is ranked worse than
95.26% of 970 companies
in the Drug Manufacturers industry
Industry Median: 0.89 vs NEOE:FH: -379.09

Filament Health FCF Margin % Historical Data

The historical data trend for Filament Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Filament Health FCF Margin % Chart

Filament Health Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

-1,084.38

-199.25

-379.09

Filament Health Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial												-68.75	-325.84	-454.55	-2,205.26	-236.32

Competitive Comparison of Filament Health's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Filament Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Filament Health's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Filament Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Filament Health's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Filament Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Filament Health's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-2.339	/	0.617
	=	-379.09 %

Filament Health's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-0.449	/	0.19
	=	-236.32 %

Filament Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of Filament Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Filament Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Filament Health Corp (NEOE:FH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

FLHLF:USA 7QS:Germany

Address

4475 Wayburne Drive, Unit 210, Burnaby, BC, CAN, V5G 4X4

Website

https://www.filament.health

Filament Health Corp is a natural psychedelic drug development company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. The group engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer's License.

Executives

Benjamin Lightburn	Director, Senior Officer
Thomas Kineshanko	10% Security Holder
Warren Duncan	Senior Officer

Filament Health Headlines

No Headlines